Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer

• Median follow-up for OS was 57.5 months in the updated analyses.
• Results of the updated OS analyses were consistent with interim analyses.
• Bevacizumab did not improve OS when added to GC therapy in this patient population.

ObjectiveOCEANS is a randomized, placebo (PL)-controlled, phase 3 trial evaluating the efficacy and safety of bevacizumab combined with gemcitabine + carboplatin (GC) for patients with platinum-sensitive recurrent ovarian cancer (ROC). The study met its primary endpoint, demonstrating improved progression-free survival with GC + bevacizumab compared with GC + PL. Herein, we describe results of final overall survival (OS) and updated safety.MethodsPatients with recurrent platinum-sensitive ROC (recurring ≥ 6 months after first-line platinum-based therapy) and measurable disease at baseline were randomized to receive GC + bevacizumab or GC + PL for 6–10 cycles; PL or bevacizumab was then continued until disease progression. In this updated analysis, a Cox proportional hazards model was used to compare OS between the 2 treatment arms.ResultsAt the data cutoff date (July 19, 2013), 353 patients (72.9%) had died. Median follow-up for OS was 58.2 months in the experimental arm and 56.4 months in the control arm. Consistent with interim analyses, median OS was comparable between arms (GC + bevacizumab: 33.6 months; GC + PL: 32.9 months; hazard ratio = 0.95; log-rank p = 0.65), and was consistent across all examined patient subgroups. The frequency and severity of adverse events were consistent with previous analyses; no new safety concerns were identified.ConclusionsResults from final OS analysis of the phase 3 OCEANS study showed no significant difference in OS for patients treated with GC + bevacizumab compared with GC + PL.